DE60319240D1 - Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen - Google Patents

Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen

Info

Publication number
DE60319240D1
DE60319240D1 DE60319240T DE60319240T DE60319240D1 DE 60319240 D1 DE60319240 D1 DE 60319240D1 DE 60319240 T DE60319240 T DE 60319240T DE 60319240 T DE60319240 T DE 60319240T DE 60319240 D1 DE60319240 D1 DE 60319240D1
Authority
DE
Germany
Prior art keywords
treatment
ligands
antigen
solid tumors
bone cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319240T
Other languages
English (en)
Inventor
Veit Prof Dr Krenn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charite Universitaetsmedizin Berlin
Original Assignee
Charite Universitaetsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin Berlin filed Critical Charite Universitaetsmedizin Berlin
Application granted granted Critical
Publication of DE60319240D1 publication Critical patent/DE60319240D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60319240T 2003-12-19 2003-12-19 Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen Expired - Lifetime DE60319240D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03029464A EP1544213B1 (de) 2003-12-19 2003-12-19 Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen

Publications (1)

Publication Number Publication Date
DE60319240D1 true DE60319240D1 (de) 2008-04-03

Family

ID=34486276

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319240T Expired - Lifetime DE60319240D1 (de) 2003-12-19 2003-12-19 Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen

Country Status (5)

Country Link
US (1) US20070148191A1 (de)
EP (1) EP1544213B1 (de)
AT (1) ATE386748T1 (de)
DE (1) DE60319240D1 (de)
WO (1) WO2005058966A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981969A4 (de) * 2006-01-19 2009-06-03 Genzyme Corp Gitr-antikörper für die krebsbehandlung
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2010027370A1 (en) * 2008-09-08 2010-03-11 The Regents Of The University Of Michigan Compositions and methods for the treatment of solid tumor cancers
BRPI1013771A2 (pt) * 2009-04-13 2016-04-05 Apceth Gmbh & Co Kg "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
CA3189470A1 (en) 2020-08-21 2022-02-24 Yves SABBAGH Fgfr3 antibodies and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
AU2002360525A1 (en) * 2001-12-06 2003-06-23 University Of Florida Targeting leukemia cells
WO2003080671A1 (en) * 2002-03-21 2003-10-02 Komed Co., Ltd. Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
EP1530474A1 (de) * 2002-07-19 2005-05-18 Ludwig Institute For Cancer Research Erhöhung der wirkung von radioimmuntherapie in der behandlung von tumoren
AU2003303521A1 (en) * 2002-12-31 2004-07-29 Genta Incorporated Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia

Also Published As

Publication number Publication date
EP1544213A1 (de) 2005-06-22
EP1544213B1 (de) 2008-02-20
US20070148191A1 (en) 2007-06-28
WO2005058966A2 (en) 2005-06-30
ATE386748T1 (de) 2008-03-15
WO2005058966A3 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
DE60332483D1 (de) Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
DE602004024909D1 (de) Platinkomplexe zur behandlung von tumoren
ATE516818T1 (de) Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
CY1117090T1 (el) Χιμαιρικες πρωτεϊνες παραγοντα πηξης για την αγωγη αιμοστατικων ασθενειων
ATE410446T1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE429442T1 (de) Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie
ATE516042T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
ATE468331T1 (de) Neue cyanopyridine-derivate zur behandlung von krebs und anderer erkrankungen
DE602006014843D1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
WO2003087831A3 (en) Proteins involved in breast cancer
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
EP1427418A4 (de) Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel und behandlungsverfahren
IL151448A0 (en) Proteins
DE60319240D1 (de) Verwendung von Liganden von CD52 Antigen zur Behandlung von soliden Tumoren und von Knochenkrebserkrankungen
ATE421324T1 (de) Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase
DE602004029767D1 (de) Detektion, überwachung und behandlung von krebs
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
ATE435647T1 (de) Rutheniumkomplexe zur krebsbehandlung

Legal Events

Date Code Title Description
8332 No legal effect for de